English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background   Synuclein-γ  has been demonstrated to be highly expressed in various human cancers including cervical cancer, and has been shown to play a critical role in tumor aggressiveness. We aimed to investigate the role of  Synuclein-γ  in human cervical cancer in vitro and in vivo.    Method  Reverse transcription-quantitative polymerase chain reaction assay and Western blot assay were used to detect the mRNA and protein expression, respectively. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and  colony formation assay  were performed to measure the viabilities of cancer cells. Flow cytometry assay was used to detect the cell cycle and apoptosis. Moreover, an animal experiment was performed to evaluate the biological behavior of  Synuclein-γ  in vivo.    Results  In the current study, we found that  Synuclein-γ  was obviously over-expressed in cervical cancer tissues compared to the adjacent non-cancer tissues. Cervical cancer cells transfected with  Synuclein-γ  siRNA demonstrated significant inhibition of cancer proliferation ( P  < 0.01), cell cycle arrest at G0/G1 phase, and cell apoptosis ( P  < 0.05). Moreover, down-regulation of  Synuclein-γ  significantly inhibited cervical cancer growth in vivo. In addition, protein levels of  AKT , c-Myc and Cyclin D1 were much lower in the  Synuclein-γ  siRNA-treated groups than that in the control group.    Conclusions   Synuclein-γ  inhibition reduced cervical cancer tumor growth through the AKT pathway. This effect represented a therapeutic opportunity and provided a novel target for cervical cancer treatment.

Silencing of Synuclein-γ inhibits human cervical cancer through the AKT signaling pathway